SG11201913014YA - Dihydro-pyrrolo-pyridine derivatives - Google Patents
Dihydro-pyrrolo-pyridine derivativesInfo
- Publication number
- SG11201913014YA SG11201913014YA SG11201913014YA SG11201913014YA SG11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA SG 11201913014Y A SG11201913014Y A SG 11201913014YA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolo
- dihydro
- pyridine derivatives
- pyridine
- derivatives
- Prior art date
Links
- JKWQHCSGMTWRIQ-UHFFFAOYSA-N 2,3-dihydro-1h-pyrrolo[3,2-b]pyridine Chemical class C1=CC=C2NCCC2=N1 JKWQHCSGMTWRIQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762523306P | 2017-06-22 | 2017-06-22 | |
PCT/IB2018/054390 WO2018234953A1 (fr) | 2017-06-22 | 2018-06-14 | Dérivés de dihydro-pyrrolo-pyridine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201913014YA true SG11201913014YA (en) | 2020-01-30 |
Family
ID=62981279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201913014YA SG11201913014YA (en) | 2017-06-22 | 2018-06-14 | Dihydro-pyrrolo-pyridine derivatives |
Country Status (19)
Country | Link |
---|---|
US (1) | US11198692B2 (fr) |
EP (1) | EP3642202B1 (fr) |
JP (1) | JP7263266B2 (fr) |
KR (1) | KR20200013783A (fr) |
CN (1) | CN110944998B (fr) |
AU (1) | AU2018287787A1 (fr) |
BR (1) | BR112019026955A2 (fr) |
CA (1) | CA3066986A1 (fr) |
DK (1) | DK3642202T3 (fr) |
ES (1) | ES2937236T3 (fr) |
FI (1) | FI3642202T3 (fr) |
HU (1) | HUE060914T2 (fr) |
IL (1) | IL271290B2 (fr) |
MX (1) | MX2019015371A (fr) |
PL (1) | PL3642202T3 (fr) |
PT (1) | PT3642202T (fr) |
SG (1) | SG11201913014YA (fr) |
TW (1) | TWI680128B (fr) |
WO (1) | WO2018234953A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
WO2024088409A1 (fr) * | 2022-10-28 | 2024-05-02 | 纽欧申医药(上海)有限公司 | Composés hétérocycliques azotés et leurs sels pharmaceutiquement acceptables, leur procédé de préparation et leur utilisation |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3123612A (en) * | 1964-03-03 | Z-acylated z | ||
US2767191A (en) * | 1953-12-31 | 1956-10-16 | American Cyanamid Co | Dihydropyrrolo-pyridines |
EP1308461A3 (fr) | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Anticorps contre des bèta-amyloides ou leurs dérivés, et leurs utilisations |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
EP0994728B1 (fr) | 1997-04-09 | 2008-07-30 | Intellect Neurosciences, Inc. | Anticorps recombines specifiques contre les terminaisons beta-amyloide, codage par molecule d'adn, et leurs procedes d'utilisation |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
JP2000109481A (ja) | 1999-10-13 | 2000-04-18 | Yamanouchi Pharmaceut Co Ltd | キヌクリジン誘導体含有医薬 |
PL218883B1 (pl) | 2000-02-24 | 2015-02-27 | Lilly Co Eli | Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
CA2427661C (fr) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Procedes d'isolement de composes inhibiteurs d'amyloide, et utilisation de composes utilises a partir d'uncaria tomentosa et de plantes parentes |
WO2003016466A2 (fr) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | Anticorps anti-$g(a)$g(b) |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
BR0315157A (pt) | 2002-10-09 | 2005-08-09 | Rinat Neuroscience Corp | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
JP2006527756A (ja) | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | Nk1拮抗薬 |
US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
CA2555071A1 (fr) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Modulateurs du recepteur de l'histamine-3 |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (fr) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine |
EP2298807A3 (fr) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Anticorps anti peptide amyloide beta, et leurs procedes d' utilisation |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
DK1807434T3 (da) | 2004-10-25 | 2010-11-22 | Lilly Co Eli | Thienopyridiner som allosteriske potentiatorer af M4- muscarinreceptoren |
US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
CA2596636C (fr) * | 2005-02-07 | 2016-04-12 | F. Hoffmann-La Roche Ag | Phenylmethanones heterocycliques substituees servant d'inhibiteurs du transporteur 1 de la glycine |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
WO2006126083A1 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Composes de pyridine [3 , 4-b] pyrazinones utilises comme inhibiteurs de pde-5 |
WO2006126081A2 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [2,3-b] pyrazinones |
CA2608672A1 (fr) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones |
US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
WO2007063385A2 (fr) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Antagonistes des recepteurs de l'histamine 3 pour des amines spirocycliques |
WO2007069053A1 (fr) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Antagonistes benzimidazoliques du récepteur h-3 |
WO2007088450A2 (fr) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagoniste du récepteur h-3 |
WO2007088462A1 (fr) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Antagonistes du récepteur du h-3 à base de spirochromane |
WO2007099423A1 (fr) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3 |
JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | H3受容体のテトラリン拮抗薬 |
DK2013208T3 (da) | 2006-04-21 | 2011-08-15 | Pfizer Prod Inc | Pyridin[3,4-B]pyrazinoner |
WO2007138431A2 (fr) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Antagonistes de l'éther histamine-3 azabicyclique |
DK2124933T3 (da) | 2007-01-22 | 2012-11-19 | Pfizer Prod Inc | Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf |
US20100273772A1 (en) * | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) |
US8664234B2 (en) | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
MX2013005454A (es) | 2010-11-15 | 2013-06-24 | Abbvie Inc | Inhibidores de nampt y rock. |
US9493481B2 (en) | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
WO2014035829A1 (fr) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Analogues de 3-aminothiéno[2,3-c]pyridine-2-carboxamide substitués utilisés comme modulateurs allostériques positifs |
WO2015027214A1 (fr) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Analogues de thiéno[2,3-c]pyridazine-6-carboxamide substitués utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
WO2015027204A1 (fr) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Analogues de thiéno[2,3-b]pyridine-2-carboxamide substitués à utiliser en tant que modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
EP3872078A1 (fr) * | 2016-07-01 | 2021-09-01 | Pfizer Inc. | Dérivés de 5,7-dihydro-pyrrolo-pyridine destinés à être utilisés dans le traitement de la dépression, l'angoisse et les troubles paniques |
GB201616839D0 (en) * | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
-
2018
- 2018-06-14 EP EP18743584.7A patent/EP3642202B1/fr active Active
- 2018-06-14 US US16/625,202 patent/US11198692B2/en active Active
- 2018-06-14 HU HUE18743584A patent/HUE060914T2/hu unknown
- 2018-06-14 WO PCT/IB2018/054390 patent/WO2018234953A1/fr unknown
- 2018-06-14 JP JP2019570547A patent/JP7263266B2/ja active Active
- 2018-06-14 KR KR1020207001865A patent/KR20200013783A/ko unknown
- 2018-06-14 IL IL271290A patent/IL271290B2/en unknown
- 2018-06-14 CA CA3066986A patent/CA3066986A1/fr active Pending
- 2018-06-14 MX MX2019015371A patent/MX2019015371A/es unknown
- 2018-06-14 DK DK18743584.7T patent/DK3642202T3/da active
- 2018-06-14 PL PL18743584.7T patent/PL3642202T3/pl unknown
- 2018-06-14 CN CN201880049365.XA patent/CN110944998B/zh active Active
- 2018-06-14 AU AU2018287787A patent/AU2018287787A1/en not_active Abandoned
- 2018-06-14 FI FIEP18743584.7T patent/FI3642202T3/fi active
- 2018-06-14 PT PT187435847T patent/PT3642202T/pt unknown
- 2018-06-14 SG SG11201913014YA patent/SG11201913014YA/en unknown
- 2018-06-14 BR BR112019026955-0A patent/BR112019026955A2/pt not_active Application Discontinuation
- 2018-06-14 ES ES18743584T patent/ES2937236T3/es active Active
- 2018-06-19 TW TW107120944A patent/TWI680128B/zh active
Also Published As
Publication number | Publication date |
---|---|
WO2018234953A1 (fr) | 2018-12-27 |
DK3642202T3 (da) | 2023-01-30 |
IL271290A (en) | 2020-01-30 |
IL271290B1 (en) | 2023-07-01 |
KR20200013783A (ko) | 2020-02-07 |
IL271290B2 (en) | 2023-11-01 |
US20200262833A1 (en) | 2020-08-20 |
EP3642202A1 (fr) | 2020-04-29 |
EP3642202B1 (fr) | 2022-11-02 |
CN110944998B (zh) | 2022-08-16 |
PL3642202T3 (pl) | 2023-03-13 |
TW201920166A (zh) | 2019-06-01 |
MX2019015371A (es) | 2020-07-20 |
CN110944998A (zh) | 2020-03-31 |
PT3642202T (pt) | 2023-02-02 |
JP2020524687A (ja) | 2020-08-20 |
CA3066986A1 (fr) | 2018-12-27 |
FI3642202T3 (fi) | 2023-03-01 |
AU2018287787A1 (en) | 2020-01-16 |
US11198692B2 (en) | 2021-12-14 |
ES2937236T3 (es) | 2023-03-27 |
HUE060914T2 (hu) | 2023-04-28 |
BR112019026955A2 (pt) | 2020-06-30 |
JP7263266B2 (ja) | 2023-04-24 |
TWI680128B (zh) | 2019-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3606954T3 (en) | Anti-LAG3-antistoffer | |
HK1255045A1 (zh) | 取代的氧代吡啶衍生物 | |
IL271607A (en) | New azaquinoline histories | |
IL253381A0 (en) | History of h9-pyrrolo-dipyridine | |
DK3499914T3 (en) | Høreapparatsystem | |
DK3700925T3 (en) | Hidtil ukendt t-cellereceptor | |
IL269038A (en) | Cryotherapy | |
AU201714106S (en) | Mandoline | |
IL274118A (en) | Binding molecules - Tri-Fab | |
DK3401557T3 (en) | Træskrue | |
DK3485765T3 (en) | Computerbord | |
IL279938A (en) | History of spirochroman | |
DK3630041T3 (en) | Stimulationsapparat | |
IL251005B (en) | Pyrido-oxazinone derivatives | |
PL3796975T3 (pl) | Pochodne sulfonyloaminobenzamidu | |
IL271290A (en) | Dihydro-pyrrolo-pyridine derivatives | |
HUE062256T2 (hu) | Dihidrokromén-származékok | |
DK3425793T3 (en) | Tagsystem | |
DK3618761T3 (en) | Intrakorporalt perfusionssystem | |
DK3351149T3 (en) | Syltetøjsfontæne | |
GB201806948D0 (en) | Derivatives | |
AU201715236S (en) | Striplight | |
AP00994S1 (en) | Autorickshaw | |
GB201708589D0 (en) | Cucurbituril-based hydrgels | |
GB201708532D0 (en) | Chattingmall |